Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 16/20 | 0.60 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | CCNK | O75909 | 1/20 | 0.42 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438253 | 0.95 | IGF1R (0.59) | IGF1RAURKAAURKBCCNKCDK13 | |
| SCHEMBL4471362 | 0.89 | IGF1R (0.76) | IGF1RAURKAAURKB | |
| SCHEMBL4457626 | 0.87 | IGF1R (0.75) | IGF1RAURKAAURKB | |
| SCHEMBL14050456 | 0.85 | IGF1R (0.60) | IGF1RAURKA | |
| SCHEMBL12439859 | 0.82 | IGF1R (0.61) | IGF1R | |
| SCHEMBL12783943 | 0.81 | AURKA (0.61) | IGF1RAURKAAURKB | |
| SCHEMBL12783953 | 0.81 | AURKA (0.54) | IGF1RAURKAAURKBCCNKCDK13 | |
| SCHEMBL4453185 | 0.80 | IGF1R (0.75) | IGF1RAURKAAURKB | |
| SCHEMBL15580728 | 0.78 | IGF1R (0.60) | IGF1RAURKAAURKB | |
| SCHEMBL11342527 | 0.78 | IGF1R (0.77) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841760-B1 | PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2011-08-10 | — | — | EP | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |